Presentation Abstract

Program#/Poster#: 41.04/G54
Presentation Title: Chronic treatment with the tetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic cholinergic and sigma-1 ligand, alleviates pathology in Tg2576 mice, a transgenic Alzheimer's disease model
Location: Halls B-H
Presentation time: Saturday, Nov 09, 2013, 4:00 PM - 5:00 PM
Topic: ++C.03.i. In vivo Abeta toxicity
1INSERM U.710, Montpellier, France; 2AMYLGEN, Montpellier, France; 3ANAVEX LIFE SCIENCES, Pallini, Greece
Abstract: Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) is a novel compound binding to muscarinic cholinergic and sigma-1 receptors with affinities in the low micromolar range. We previously reported that the drug showed anti-amnesic and neuroprotective potential in the Alzheimer's disease (AD) model in mice induced by the icv injection of oligomeric amyloid(25-35) peptide. In particular, the drug attenuated the oxidative stress, caspases induction, cellular loss, Aß1-42 seeding, Tau hyperphosphorylation, mitochondrial dysfunction and learning and memory deficits observed several days after Aß25-35 injection. The mechanism of action appeared to involve synergically muscarinic cholinergic receptors and the sigma-1 chaperone protein, a potent sensor/modulator of cellular responses. In the present study, we treated 10-month old Tg2576 mice, overexpressing the swedish hAPP mutation,, with ANAVEX2-73, 3 mg/kg/day per os, during two months. 40 male and 60 female mice were used and data were analyzed for each gender and globally. Vehicle-treated Tg2576 showed significant alterations of spontaneous alternation in Y-maze at 11 and 12 month of age and of place learning in the water-maze at 12 months. These deficits were prevented by the ANAVEX2-73 treatment. Animals were sacrificed after the behavioral procedures and used for biochemical analyses. Tg2576 mice presented an increased cerebral oxidative stress (measured by oxidation rate of dichlorofuorescein diacetate) and a synaptic alteration (measured by a decrease in synaptophysin content). Both were normalized in ANAVEX2-73 treated mice. We confirmed a positive impact of the compound on brain plasticity by measuring (by qPCR analysis) increased expression of Arc, Egr-1, NR2A, NR2B and PSD95 mRNA. However, the compound only marginally decreased soluble and insoluble Aß1-42 brain contents, and only in male mice. Morphological analyses are in progress. This first set of data confirmed the efficacy of the mixed muscarinic cholinergic receptor ligand and sigma-1 receptor agonist in a chronic transgenic mouse model of AD. The compound allows an effective brain protection during the most aggressive phase of the pathology.
Disclosures:   T. Maurice: B. Contracted Research/Research Grant (principal investigator for a drug study, collaborator or consultant and pending and current grants). If you are a PI for a drug study, report that research relationship even if those funds come to an institution.; ANAVEX LIFE SCIENCES. F. Consulting Fees (e.g., advisory boards); AMYLGEN. V. Lahmy: A. Employment/Salary (full or part-time):; CIFRE funding AMYLGEN. V. Villard: A. Employment/Salary (full or part-time):; AMYLGEN. A. Vamvakides: A. Employment/Salary (full or part-time):; ANAVEX LIFE SCIENCES.

Note: When adding items to your Itinerary, please click "Add Checked Selections to My Itinerary" on EACH page of your search results.

At the Meeting






Fellowships, Awards, and Prizes

Frequently Asked Questions

Final Program


Download Abstracts and
Daily Books to Your E-Reader Devices